Clinical Trials Directory

Trials / Unknown

UnknownNCT06157619

Vitrification of Oocytes Matured by CAPA-IVM

Vitrification of In Vitro Matured Oocytes Following the CAPA-IVM Methodology

Status
Unknown
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
Centro de Fertilidad y Reproducción Asistida, Peru · Academic / Other
Sex
Female
Age
20 Years – 37 Years
Healthy volunteers
Accepted

Summary

It has been reported that the potential of In Vitro matured oocytes might be affected by the vitrification process. In fact, the freezing and thawing procedures routinely used in IVF laboratories, have not yet been adapted to oocytes coming from early antral follicles (normally used for In Vitro Maturation). This study aims to compare 2 existing protocols for the Vitrification of In Vitro matured oocytes.

Detailed description

This is a single-center non-blinded observational study. The proposed study will follow a sibling oocyte design in infertile patients. In Vitro Maturation will be performed by using the Capacitation-IVM (CAPA-IVM) methodology. All cumulus-oocyte complexes (COC) recovered from the patient will be cultured in CAPA medium for 24 hours and then matured for 30 hours (IVM). A minimum of 10 metaphase II (MII) stage oocytes are expected from each CAPA-IVM procedure. After CAPA-IVM culture, the mature oocytes (MII) will be randomly divided (50/50) into two groups to be subjected to the two vitrification protocols. In a second step (next cycle), the oocytes from each group will be thawed and fertilized by Intracytoplasmic sperm injection (ICSI). The derived embryos will be cultured to the blastocyst stage (Day 5/6). The transfer of a single embryo (the one with the best quality) will be carried out. The remaining embryos will be vitrified.

Conditions

Interventions

TypeNameDescription
PROCEDUREOocyte Vitrification /WarmingIn Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols

Timeline

Start date
2023-12-01
Primary completion
2024-05-01
Completion
2025-03-01
First posted
2023-12-06
Last updated
2023-12-06

Locations

1 site across 1 country: Peru

Source: ClinicalTrials.gov record NCT06157619. Inclusion in this directory is not an endorsement.